Please assess the completion status of the following clinical trial:

Trial Title: Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 7 years of age or older and able to perform pulmonary function testing~2. Confirmed diagnosis of CF by the 1997 CF Consensus Conference criteria and followed by the VCU or EVMS CF clinic~3. Presence of PA in 2 lower respiratory tract (sputum) cultures in the 24 months before screening~4. Subjects and/or parent guardian must be able to give written informed consent prior to any study related procedure~5. All sexually active female subjects who are of childbearing potential must agree to use an effective method of contraception (i.e.condoms or abstinence).~6. All sexually active female subjects must have a negative pregnancy test at screening (V0).~7. Clinically stable determined by the study physician with no significant new respiratory symptoms.~8. Presence of PA in nasal culture (swab or secretion) or sinus culture obtained in the 12 months before screening or at screening visit~Exclusion Criteria:~1. Use of oral, IV or inhaled antibiotics within 0 days before study other than low dose azithromycin~2. Severe pulmonary disease with FEV1\<30% predicted of baseline SpO2\<0.90~3. ENT surgery within 6 months of screening~4. Allergy or documented adverse reaction to aztreonam~5. Epistaxis or significant (\>30mL) hemoptysis in the past 6 months~6. Frequent (weekly or more frequently) or severe headaches~7. Subject is unlikely to comply with the procedures scheduled in the protocol~8. Subject participates in another clinical trial within 30 days prior to study entry~9. Subjects who have had a lung transplant will be excluded~10. Prisoners will be excluded~11. Non-English Speaking patients will be excluded

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Standard Therapy (Type: ACTIVE_COMPARATOR): Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
- Study Therapy (Type: EXPERIMENTAL): Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).